Neural progenitor cell differentiation

US9896656B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9896656-B2
Application numberUS-201414216391-A
CountryUS
Kind codeB2
Filing dateMar 17, 2014
Priority dateMar 15, 2013
Publication dateFeb 20, 2018
Grant dateFeb 20, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets. The matrix compositions of the present invention can be used to tissue engineer transplantable innervated GI smooth muscle constructs to remedy aganglionic disorders.

First claim

Opening claim text (preview).

The invention claimed is: 1. A transplantable innervated smooth muscle construct, comprising: a biocompatible hydrogel substrate comprising at least one of collagen, laminin and heparan sulfate; a population of longitudinal smooth muscle cells of enteric origin formed as a muscle cell sheet on a mold containing a wavy microtopography and disposed in contact with the hydrogel substrate; and a population of neural stem cells initially seeded in the hydrogel and induced to differentiate and innervate the muscle cell sheet. 2. The construct of claim 1 wherein the smooth muscle cell sheet further comprises axially-aligned longitudinal smooth muscle cells. 3. The construct of claim 1 wherein the hydrogel comprises collagen. 4. The construct of claim 1 wherein the hydrogel comprises at least 800 μg/ml of collagen type I. 5. The construct of claim 1 wherein the hydrogel further comprises at least 200 μg/ml of collagen type IV. 6. The construct of claim 1 wherein the hydrogel further comprises at least 5 μg/ml of laminin. 7. The construct of claim 1 wherein the hydrogel is substantially free of laminin. 8. The construct of claim 1 wherein the hydrogel is substantially free of heparan sulfate. 9. The construct of claim 1 wherein the hydrogel comprises a hydrogel sponge with effective pore sizes ranging from 10 nanometers to 10 micrometers. 10. The construct of claim 1 wherein the neural stem cells are differentiated into at least one neuronal subtype. 11. The construct of claim 10 wherein the substrate comprises collagen I and the at least one neuronal subtype comprises cholinergic neurons. 12. The construct of claim 10 wherein the substrate comprises collagen I and collagen IV and the at least one neuronal subtype comprises nitrergic neurons. 13. The construct of claim 10 wherein the substrate comprises laminin and heparan sulfate and the at least one neuronal subtype comprises peptidergic neurons. 14. The construct of claim 10 wherein the substrate is substantially free of laminin and heparan sulfate and the at least one neuronal subtype comprises glial cells.

Assignees

Inventors

Classifications

  • Collagen; Gelatin · CPC title

  • Fibronectin; Laminin · CPC title

  • Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells · CPC title

  • Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title

  • Substrates of biological origin, e.g. extracellular matrix, decellularised tissue · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9896656B2 cover?
Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combi…
Who is the assignee on this patent?
Univ Wake Forest Health Sciences
What technology area does this patent fall under?
Primary CPC classification C12N5/0619. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).